EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV

Matteo Vassallo, Jacques Durant, Roxane Fabre iD, Jacqueline Capeau iD, Soraya Fellahi iD, Jean-Philippe Bastard iD, Pierre Corbeau iD, Christian Pradier

Pathogens · 14.03.2026 · 15 (3) · 316

DOI: 10.3390/pathogens15030316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 14.03.2026. Verfasst von Matteo Vassallo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, 06400 Cannes, France. Hauptthemen laut MEDLINE: HIV Infections, Biomarkers, HIV Integrase Inhibitors, Integrase Inhibitors. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite improvements in life expectancy, people living with HIV (PWH) continue displaying immune activation and high rates of comorbid conditions. No comparative studies concerning activation markers exist between simplification strategies to either oral or long-acting (LA) dual ART.

Methods

We prospectively collected plasma samples from PWH on successful ART, simplifying treatment from triple oral to either oral or LA dual ART based on integrase inhibitors. We measured changes in soluble CD14 (sCD14), soluble CD163 (sCD163), monocyte chemoattractant protein-1, and interleukin-6. Background measurements and markers of microbial translocation and gut integrity (I-FABP, LBP) were also collected.

Results

From 2019 to 2023, 38 PWH were analyzed (mean age 52, 87% male, 21 years HIV diagnosis, CD4 730 cells/mm3, nadir CD4 317 cells/mm3, AIDS 13%). After 7.2 months, sCD14 trajectories differed according to regimen (+0.43 ng/mL, p = 0.033 for LA ART, −0.62 ng/mL, p < 0.001 for oral ART) but were not related to I-FABP or to LBP values. In case of CD4 nadir < 200 cc/mm3, AIDS, or very-low-level viremia, sCD163 values significantly increased when switching to oral but not to LA dual ART.

Conclusion

We found different trends in immune activation markers and risk factors associated with PWH switching to either oral or LA ART, requiring larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsBiomarkersHIV Integrase InhibitorsIntegrase InhibitorsAnti-Retroviral AgentsHumansMaleFemaleMiddle AgedCD163 AntigenAdultAntigens, CDAntigens, Differentiation, MyelomonocyticAdministration, OralLipopolysaccharide ReceptorsProspective StudiesReceptors, Cell SurfaceInterleukin-6

Stichwörter der Autor:innen

HIVdual drug regimenimmune activationsimplification strategies

Substanzen

BiomarkersCD163 AntigenAntigens, CDAntigens, Differentiation, MyelomonocyticLipopolysaccharide ReceptorsReceptors, Cell SurfaceHIV Integrase InhibitorsIntegrase InhibitorsAnti-Retroviral AgentsInterleukin-6

Autor:innen und Institutionen

  • Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, 06400 Cannes, France.
  • Unité de Recherche Clinique Cote d'Azur (Unité de Recherche Radiologically Isolated Syndrome), Université Côte d'Azur, 06000 Nice, France.
  • Department of Infectious Diseases, Archet Hospital, Nice University, 06202 Nice, France.
  • Public Health Department, Archet Hospital, Nice University, 06202 Nice, France.
  • Pain Department and FHU InovPain, Nice University Hospital, Cote Azur University, 06000 Nice, France.
  • Institut Hospitalo-Universitaire de Cardiométabolisme et Nutrition (ICAN), RHU CARMMA, Centre de Recherche Saint-Antoine, INSERM UMR_S 938, Sorbonne Université, 75012 Paris, France.

ORCID-Profile: Roxane Fabre, Jacqueline Capeau, Soraya Fellahi, Jean-Philippe Bastard, Pierre Corbeau

Zitieren

APA

Vassallo, M., Durant, J., Fabre, R., Capeau, J., Fellahi, S., Bastard, J. P., Corbeau, P., & Pradier, C. (2026). Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV. Pathogens, 15(3), 316. https://doi.org/10.3390/pathogens15030316

Vancouver

Vassallo M, Durant J, Fabre R, Capeau J, Fellahi S, Bastard JP, et al. Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV. Pathogens. 2026;15(3):316. doi:10.3390/pathogens15030316

BibTeX
@article{Vassallo2026,
  author = {Vassallo, Matteo and Durant, Jacques and Fabre, Roxane and Capeau, Jacqueline and Fellahi, Soraya and Bastard, Jean-Philippe and Corbeau, Pierre and Pradier, Christian},
  title = {Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {316},
  doi = {10.3390/pathogens15030316}
}
Kostenlos starten →